Clinical Trial Update: Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety, tolerability, and pharmacokinetics of CHF6523 in healthy individuals and patients with chronic obstructive pulmonary disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF6523

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD | Phase 1 | Status: COMPLETED